Clinical trials: Movement Abnormalities
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
The primary objective of the study was to evaluate the efficacy and safety of UX007 in the treatment of disabling paroxysmal movement disorders associated with Glut1 DS.
- Trial name
- NCT02960217
- Testing
- UX007
- Where
- 12 sites in United States, France and 4 more
- Volunteers
- 44 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Parkinson Disease
Advancing Pre-operative Targeting for Deep Brain Stimulation in the Globus Pallidus Internus
In the proposed pilot project, MRI data will be prospectively collected to show the feasibility of the segmentation algorithm and the potential relation to final lead positioning.
- Trial name
- NCT03600740
- Testing
- DBS Programming
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Parkinson Disease
Sing for Your Saunter
Older adults, and particularly those with Parkinson disease (PD), may experience walking difficulties that negatively impact their daily function and quality of life.
- Trial name
- SFYS (NCT04246476)
- Testing
- Mentally singing, Listening to music
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Dementia, Alzheimer Disease
Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers
The goal of this clinical trial is to evaluate Kinto's Care Coaching intervention for dementia caregivers. The main questions it aims to answer are: Does the intervention help caregivers to address their general caregiving goals…
- Conditions
- Dementia, Alzheimer Disease, Lewy Body Disease, Vascular Dementia
- Trial name
- NCT05916664
- Testing
- Kinto Care Coaching
- Where
- United States
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- Kinto
Parkinson Disease
a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients
This is an open-label, multicenter, non-interventional, prospective observational study. we collect the safety information of pramipexole over 12w treatment.
- Trial name
- NCT01361009
- Testing
- pramipexole
- Where
- 103 sites in China
- Volunteers
- 2,017 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.
- Trial name
- NCT00522379
- Testing
- Rotigotine
- Where
- 77 sites in United States, Chile and 3 more
- Volunteers
- 514 people
- Sponsor
- UCB Pharma
Parkinson Disease, Off Episodes
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to determine the efficacy, safety and…
- Trial name
- NCT02469090
- Testing
- APL-130277
- Where
- 33 sites in United States, Canada
- Volunteers
- 141 people
- Sponsor
- Sumitomo Pharma America, Inc.
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/carbidopa 100/25 mg…
- Trial name
- NCT02169479
- Testing
- BIA 9-1067, Sinemet® 100/25
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
IDIOPATHIC PARKINSON'S DISEASE
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
The primary objective is to demonstrate that the Rotigotine transdermal patch is efficacious in Chinese subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- NCT01646268
- Testing
- Rotigotine
- Where
- 24 sites in China
- Volunteers
- 249 people
- Sponsor
- UCB Pharma
Tourette Syndrome
Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
The primary objective of this open-label, flexible dose study is to assess the safety and efficacy of pramipexole over a 24-week period in children and adolescents (age 6-17 years inclusive) diagnosed with Tourette Syndrome…
- Trial name
- NCT00681863
- Testing
- pramipexole 0.125 mg BID, pramipexole 0.0625 mg QD, pramipexole 0.125 mg TID
- Where
- 14 sites in United States, Germany
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Tourette Syndrome
Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole versus placebo for 6 weeks in children (age 6-17) diagnosed with Tourette Disorder according to DSM IV criteria.
- Trial name
- NCT00558467
- Testing
- pramipexole immediate release (IR)
- Where
- 16 sites in United States, Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Diffuse Lewy Body Disease, Dementia With Lewy Bodies
Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
This study uses a special type of scan called a positron emission tomography (PET) scan to take pictures of the brain. During the PET scan, a special dye called 11C-PBR28 is injected into the body.
- Conditions
- Diffuse Lewy Body Disease, Dementia With Lewy Bodies, Parkinson's Disease Dementia
- Trial name
- NCT02702102
- Testing
- 11C-PBR28
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Columbia University
Huntington Disease, Chorea
Atomoxetine and Huntington's Disease
The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking ability and muscle movements…
- Trial name
- NCT00368849
- Testing
- atomoxetine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa
Parkinson's Disease, Sleep Disorder; Excessive Somnolence
Light Therapy Treatment in Parkinson's Disease Patients With Daytime Somnolence
Study objectives are to determine the efficacy, safety and tolerability of bright light treatment in Parkinson's Disease (PD) patients with daytime sleepiness.
- Trial name
- NCT01338649
- Testing
- Bright Light Treatment (Sun Ray Sunbox SB-558), Dim red light (Sun Ray Sunbox SB-558)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Huntington's Disease, Chorea
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
- Trial name
- NCT07601516
- Testing
- Deutetrabenazine
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Parkinson's Disease, Mild Cognitive Impairment
Cognitive Rehab for Parkinson's
This study will examine the feasibility of an at-home cognitive training program that incorporates both memory training and online computerized cognitive training (CCT) software.
- Trial name
- NCT03836963
- Testing
- cognitive training, active control cognitive training, memory strategy training
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- VA Office of Research and Development
Tourette Syndrome
Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
This is an investigator-initiated proof of concept study with the purpose to examine the safety, tolerability and feasibility of Dronabinol (synthetic Δ9-THC) and PEA for the treatment of adults with Tourette syndrome.
- Trial name
- NCT03066193
- Testing
- Dronabinol and Palmitoylethanolamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Huntington's Disease
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920.
- Trial name
- NCT02342548
- Testing
- 20 mg BID of PF-02545920
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Tourette Syndrome, Tic Disorder, Chronic Motor or Vocal
Open-label MNS for Tourette Syndrome
A recent report (Morera Maiquez et al 2020) described reduced tic severity in people with Tourette syndrome during 1-minute epochs of median nerve stimulation (MNS) at 10 Hz.
- Trial name
- NCT05016765
- Testing
- Active, self-directed electrical stimulation of the median nerve
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Washington University School of Medicine
Huntington's Disease
Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)
To establish the tolerability of treatment with 600, 1200 or 2400 mg per day of coenzyme Q10 in pre-manifest participants carrying the CAGn expansion for Huntington's Disease (HD).
- Trial name
- PREQUEL (NCT00920699)
- Testing
- CoQ10
- Where
- 13 sites in United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University